|
1
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gill S, Loprinzi CL, Sargent DJ, Thomé SD,
Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE,
Francois Seitz J, et al: Pooled analysis of fluorouracil-based
adjuvant therapy for stage II and III colon cancer: Who benefits
and by how much? J Clin Oncol. 22:1797–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyerhardt JA: Adjuvant therapy for stage
II and III colon cancer. Clin Adv Hematol Oncol. 8:772–774.
2010.PubMed/NCBI
|
|
4
|
Wu C: Systemic therapy for colon cancer.
Surg Oncol Clin N Am. 27:235–242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li J, Guo BC, Sun LR, Wang JW, Fu XH,
Zhang SZ, Poston G and Ding KF: TNM staging of colorectal cancer
should be reconsidered by T stage weighting. World J Gastroenterol.
20:5104–5112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallois C, Pernot S, Zaanan A and Taieb J:
Colorectal cancer: Why does side matter? Drugs. 78:789–798. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duffy MJ: Carcinoembryonic antigen as a
marker for colorectal cancer: Is it clinically useful? Clin Chem.
47:624–630. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: an iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Wei Z, Pan K, Li J and Chen Q: The
function and mechanism of ferroptosis in cancer. Apoptosis.
25:786–798. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushita M, Freigang S, Schneider C,
Conrad M, Bornkamm GW and Kopf M: T cell lipid peroxidation induces
ferroptosis and prevents immunity to infection. J Exp Med.
212:555–568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Hambright WS, Na R and Ran Q:
Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in
neurons results in rapid motor neuron degeneration and paralysis. J
Biol Chem. 290:28097–28106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi ZZ, Fan ZW, Chen YX, Xie XF, Jiang W,
Wang WJ, Qiu YT and Bai J: Ferroptosis in carcinoma: Regulatory
mechanisms and new method for cancer therapy. Onco Targets Ther.
12:11291–11304. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen P, Li X, Zhang R, Liu S, Xiang Y,
Zhang M, Chen X, Pan T, Yan L, Feng J, et al: Combinative treatment
of β-elemene and cetuximab is sensitive to KRAS mutant colorectal
cancer cells by inducing ferroptosis and inhibiting
epithelial-mesenchymal transformation. Theranostics. 10:5107–5119.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma P, Shimura T, Banwait JK and Goel
A: Andrographis-mediated chemosensitization through activation of
ferroptosis and suppression of β-catenin/Wnt-signaling pathways in
colorectal cancer. Carcinogenesis. 41:1385–1394. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimura T, Sharma P, Sharma GG, Banwait JK
and Goel A: Enhanced anti-cancer activity of andrographis with
oligomeric proanthocyanidins through activation of metabolic and
ferroptosis pathways in colorectal cancer. Sci Rep. 11:75482021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma R, Shimura T, Yin C, Okugawa Y,
Kitajima T, Koike Y, Okita Y, Ohi M, Uchida K, Goel A, et al:
Antitumor effects of andrographis via ferroptosis-associated genes
in gastric cancer. Oncol Lett. 22:5232021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun
X, Kang R and Tang D: Ferroptosis: Process and function. Cell Death
Differ. 23:369–379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma A and Flora SJS: Positive and
negative regulation of ferroptosis and its role in maintaining
metabolic and redox homeostasis. Oxid Med Cell Longev.
2021:90742062021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Li J, Kang R, Klionsky DJ and Tang
D: Ferroptosis: Machinery and regulation. Autophagy. 17:2054–2081.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ouyang S, Li H, Lou L, Huang Q, Zhang Z,
Mo J, Li M, Lu J, Zhu K, Chu Y, et al: Inhibition of
STAT3-ferroptosis negative regulatory axis suppresses tumor growth
and alleviates chemoresistance in gastric cancer. Redox Biol.
52:1023172022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu W, Zhang C, Wu R, Sun Y, Levine A and
Feng Z: Glutaminase 2, a novel p53 target gene regulating energy
metabolism and antioxidant function. Proc Natl Acad Sci USA.
107:7455–7460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu S, Li T, Liu W and Huang Y: Ferroptosis
and cancer: Complex relationship and potential application of
exosomes. Front Cell Dev Biol. 9:7337512021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimura T, Toiyama Y, Tanaka K, Saigusa S,
Kitajima T, Kondo S, Okigami M, Yasuda H, Ohi M, Araki T, et al:
Angiopoietin-like protein 2 as a predictor of early recurrence in
patients after curative surgery for gastric cancer. Anticancer Res.
35:4633–4639. 2015.PubMed/NCBI
|
|
31
|
Ichikawa T, Okugawa Y, Toiyama Y, Tanaka
K, Yin C, Kitajima T, Kondo S, Shimura T, Ohi M, Araki T and
Kusunoki M: Clinical significance and biological role of L1 cell
adhesion molecule in gastric cancer. Br J Cancer. 121:1058–1068.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mori K, Toiyama Y, Otake K, Ide S, Imaoka
H, Okigami M, Okugawa Y, Fujikawa H, Saigusa S, Hiro J, et al:
Successful identification of a predictive biomarker for lymph node
metastasis in colorectal cancer using a proteomic approach.
Oncotarget. 8:106935–106947. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shigemori T, Toiyama Y, Okugawa Y,
Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa
H, et al: Soluble PD-L1 expression in circulation as a predictive
marker for recurrence and prognosis in gastric cancer: Direct
comparison of the clinical burde between tissue and serum PD-L1
expression. Ann Surg Oncol. 26:876–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stewart MJ and Watson ID: Standard units
for expressing drug concentrations in biological fluids. Br J Clin
Pharmacol. 16:3–7. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Y, Zhang Z, Sun W, Zhang J, Xu Q,
Zhou X and Mao L: Ferroptosis in colorectal cancer: Potential
mechanisms and effective therapeutic targets. Biomed Pharmacother.
153:1135242022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang X, You Z, Chen X and Li J: Targeting
ferroptosis in colorectal cancer. Metabolites. 12:7452022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen HHW and Kuo MT: Role of glutathione
in the regulation of Cisplatin resistance in cancer chemotherapy.
Met Based Drugs. 2010:4309392010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sui X, Zhang R, Liu S, Duan T, Zhai L,
Zhang M, Han X, Xiang Y, Huang X, Lin H and Xie T: RSL3 drives
ferroptosis through GPX4 inactivation and ROS production in
colorectal cancer. Front Pharmacol. 9:13712018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tian X, Li S and Ge G: Apatinib promotes
ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4
signaling. Cancer Manag Res. 13:1333–1342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chaudhary N, Choudhary BS, Shah SG,
Khapare N, Dwivedi N, Gaikwad A, Joshi N, Raichanna J, Basu S,
Gurjar M, et al: Lipocalin 2 expression promotes tumor progression
and therapy resistance by inhibiting ferroptosis in colorectal
cancer. Int J Cancer. 149:1495–1511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang R, Su Q, Yin H, Wu D, Lv C and Yan Z:
Inhibition of SRSF9 enhances the sensitivity of colorectal cancer
to erastin-induced ferroptosis by reducing glutathione peroxidase 4
expression. Int J Biochem Cell Biol. 134:1059482021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang R, Fu J, Ge Y, Ren J, Song W and Fu
T: Identification of subtypes and a prognostic gene signature in
colon cancer using cell differentiation trajectories. Front Cell
Dev Biol. 9:7055372021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ousingsawat J, Schreiber R and Kunzelmann
K: TMEM16F/anoctamin 6 in ferroptotic cell death. Cancers (Basel).
11:6252019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo C, Liu P, Deng G, Han Y, Chen Y, Cai
C, Shen H, Deng G and Zeng S: Honokiol induces ferroptosis in colon
cancer cells by regulating GPX4 activity. Am J Cancer Res.
11:3039–3054. 2021.PubMed/NCBI
|
|
46
|
Chen Y, Zhang F, Du Z, Xie J, Xia L, Hou
X, Hao E and Deng J: Proteome analysis of Camellia nitidissima Chi
revealed its role in colon cancer through the apoptosis and
ferroptosis pathway. Front Oncol. 11:7271302021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He J, Ding H, Li H, Pan Z and Chen Q:
Intra-tumoral expression of SLC7A11 is associated with immune
microenvironment, drug resistance, and prognosis in cancers: A
pan-cancer analysis. Front Genet. 12:7708572021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gnanapradeepan K, Basu S, Barnoud T,
Budina-Kolomets A, Kung CP and Murphy ME: The p53 tumor suppressor
in the control of metabolism and ferroptosis. Front Endocrinol
(Lausanne). 9:1242018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei G, Sun J, Hou Z, Luan W, Wang S, Cui
S, Cheng M and Liu Y: Novel antitumor compound optimized from
natural saponin Albiziabioside A induced caspase-dependent
apoptosis and ferroptosis as a p53 activator through the
mitochondrial pathway. Eur J Med Chem. 157:759–772. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wei R, Zhao Y, Wang J, Yang X, Li S, Wang
Y, Yang X, Fei J, Hao X, Zhao Y, et al: Tagitinin C induces
ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal
cancer cells. Int J Biol Sci. 17:2703–2717. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang L, WenTao T, ZhiYuan Z, Qi L, YuXiang
L, Peng Z, Ke L, XiaoNa J, YuZhi P, MeiLing J, et al: Cullin-9/p53
mediates HNRNPC degradation to inhibit erastin-induced ferroptosis
and is blocked by MDM2 inhibition in colorectal cancer. Oncogene.
41:3210–3221. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cancer Genome Atlas Research Network;
Analysis Working Group; Asan University; BC Cancer Agency; Brigham
and Women's Hospital; Broad Institute; Brown University; Case
Western Reserve University; Dana-Farber Cancer Institute; Duke
University; Greater Poland Cancer Centre, et al, . Integrated
genomic characterization of oesophageal carcinoma. Nature.
541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shao Y, Jia H, Huang L, Li S, Wang C,
Aikemu B, Yang G, Hong H, Yang X, Zhang S, et al: An original
ferroptosis-related gene signature effectively predicts the
prognosis and clinical status for colorectal cancer patients. Front
Oncol. 11:7117762021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chatterjee S and Burns TF: Targeting heat
shock proteins in cancer: A promising therapeutic approach. Int J
Mol Sci. 18:19782017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu J, Liu T, Rios Z, Mei Q, Lin X and Cao
S: Heat shock proteins and cancer. Trends Pharmacol Sci.
38:226–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X,
Wang H, Cao L and Tang D: HSPB1 as a novel regulator of ferroptotic
cancer cell death. Oncogene. 34:5617–5625. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Garrido C, Brunet M, Didelot C, Zermati Y,
Schmitt E and Kroemer G: Heat shock proteins 27 and 70:
Anti-apoptotic proteins with tumorigenic properties. Cell Cycle.
5:2592–2601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cheng J, Lv Z, Weng X, Ye S, Shen K, Li M,
Qin Y, Hu C, Zhang C, Wu J and Zheng S: Hsp27 acts as a master
molecular chaperone and plays an essential role in hepatocellular
carcinoma progression. Digestion. 92:192–202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu CL, Chen SF, Wu MZ, Jao SW, Lin YS,
Yang CY, Lee TY, Wen LW, Lan GL and Nieh S: The molecular and
clinical verification of therapeutic resistance via the p38
MAPK-Hsp27 axis in lung cancer. Oncotarget. 7:14279–14290. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Oesterreich S, Weng CN, Qiu M, Hilsenbeck
SG, Osborne CK and Fuqua SA: The small heat shock protein hsp27 is
correlated with growth and drug resistance in human breast cancer
cell lines. Cancer Res. 53:4443–4448. 1993.PubMed/NCBI
|
|
63
|
Shimada T, Tsuruta M, Hasegawa H,
Okabayashi K, Shigeta K, Ishida T, Asada Y, Suzumura H, Koishikawa
K, Akimoto S and Kitagawa Y: Heat shock protein 27 knockdown using
nucleotide-based therapies enhances sensitivity to 5-FU
chemotherapy in SW480 human colon cancer cells. Oncol Rep.
39:1119–1124. 2018.PubMed/NCBI
|
|
64
|
Liang HH, Huang CY, Chou CW, Makondi PT,
Huang MT, Wei PL and Chang YJ: Heat shock protein 27 influences the
anti-cancer effect of curcumin in colon cancer cells through ROS
production and autophagy activation. Life Sci. 209:43–51. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hayashi R, Ishii Y, Ochiai H, Matsunaga A,
Endo T, Hasegawa H and Kitagawa Y: Suppression of heat shock
protein 27 expression promotes 5-fluorouracil sensitivity in colon
cancer cells in a xenograft model. Oncol Rep. 28:1269–1274. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ishida T, Ishii Y, Tsuruta M, Okabayashi
K, Akimoto S, Koishikawa K, Hasegawa H and Kitagawa Y: Cetuximab
promotes SN38 sensitivity via suppression of heat shock protein 27
in colorectal cancer cells with wild-type RAS. Oncol Rep.
38:926–932. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu Z, Liu Y, Long Y, Liu B and Wang X:
Role of HSP27 in the multidrug sensitivity and resistance of colon
cancer cells. Oncol Lett. 19:2021–2027. 2020.PubMed/NCBI
|
|
68
|
Yang WS and Stockwell BR: Synthetic lethal
screening identifies compounds activating iron-dependent,
nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.
Chem Biol. 15:234–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Dixon SJ, Winter GE, Musavi LS, Lee ED,
Snijder B, Rebsamen M, Superti-Furga G and Stockwell BR: Human
haploid cell genetics reveals roles for lipid metabolism genes in
nonapoptotic cell death. ACS Chem Biol. 10:1604–1609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang X, Ma Y, Ma J, Yang L, Song Q, Wang
H and Lv G: Glutathione peroxidase 4 as a therapeutic target for
anti-colorectal cancer drug-tolerant persister cells. Front Oncol.
12:9136692022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Benson AB, Venook AP, Al-Hawary MM, Arain
MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, et
al: Colon cancer, version 2.2021, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 19:329–359. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hashiguchi Y, Muro K, Saito Y, Ito Y,
Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M,
et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2019 for the treatment of colorectal cancer. Int J Clin
Oncol. 25:1–42. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yamazaki K, Yamanaka T, Shiozawa M, Manaka
D, Kotaka M, Gamoh M, Shiomi A, Makiyama A, Munemoto Y, Rikiyama T,
et al: Oxaliplatin-based adjuvant chemotherapy duration (3 vs. 6
months) for high-risk stage II colon cancer: The randomized phase
III ACHIEVE-2 trial. Ann Oncol. 32:77–84. 2021. View Article : Google Scholar : PubMed/NCBI
|
